Karuna Therapeutics Net Income

Karuna Therapeutics posts a net income of $-420M as of December 2023. That compares with $-280M in the prior-year period — down 52.8% year over year. That is below the Healthcare sector average of $16B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Karuna Therapeutics's net income was $-280M. The latest reading is $-420M — a 52.8% year-over-year decrease (period ending December 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a net income near $16B is typical. Karuna Therapeutics's $-420M is lower that level. That is roughly 102.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Karuna Therapeutics's financial statement story. At $-420M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for KRTX's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $16B), and (3) consistency with growth and profitability. This page covers the first two; Karuna Therapeutics's other metric pages and overview cover the third.